TXG - Latest News
10x Genomics, Inc. (TXG), operates in Healthcare / Medical - Healthcare Information Services, trades on NASDAQ.
Market capitalization stands near $2.67B. Beta to the broader market is 2.05.
The article list below shows the most recent TXG headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent TXG Headlines
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com - May 13, 2026
10x Genomics, Inc.
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%
fool.com - May 12, 2026
10x Genomics provides advanced tools for single cell and spatial biology research, serving academic and biopharma institutions worldwide.
Torex Gold Resources Inc. (TXG:CA) Q1 2026 Earnings Call Transcript
seekingalpha.com - May 9, 2026
Torex Gold Resources Inc.
10x Genomics Q1 Earnings Call Highlights
marketbeat.com - May 9, 2026
10x Genomics NASDAQ: TXG reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the
10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
zacks.com - May 8, 2026
TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.
How News Affects TXG Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track TXG's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked TXG news questions
- What is the latest TXG news headline?
- The most recent TXG headline (May 13, 2026) is "10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the TXG news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What TXG news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual TXG options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.